Lorlatinib
Lorlatinib (PF-6463922) is a potent, orally bioavailable small molecule inhibitor targeting ALK and ROS1 tyrosine kinases. It is widely used in preclinical oncology research to investigate resistance mechanisms and evaluate antitumor efficacy in both cellular assays and animal models of non-small cell lung cancer.
Product Specifications
CAS Number
1454846-35-5
Product Name Alternative
Cluster of differentiation 246, CD246, ALK, ALK (L1196M), ALK tyrosine kinase receptor, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase (ALK), Apoptosis, brain-penetrant, Carcinoma, NSCLC, Neuroblastoma, LTK (TYK1), Lorlatinib, Loratinib, kinase, inhibit, mutation, Inhibitor, PF-6463922, PF6463922, PF 6463922, PF06463922, PF-06463922, PF 06463922, third-generation, ROS, ROS1, ROSKinase, ROS Kinase, TyrosineKinases, Tyrosine Kinases, tyrosine
Field of Research
Cardiovascular Research, Cell Biology, Immunology & Inflammation, Pharmacology & Drug Discovery, Signal Transduction
Purity
99.77% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.92 mM) ; Ethanol:40.6 mg/mL (99.9 mM) ; DMSO:13 mg/mL (31.99 mM)
Smiles
C[C@H]1Oc2cc (cnc2N) -c2c (CN (C) C (=O) c3ccc (F) cc13) nn (C) c2C#N
Molecular Formula
C21H19FN6O2
Molecular Weight
406.41
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
